{
    "xml": "<topic id=\"PHP3604\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/ethambutol-hydrochloride\" basename=\"ethambutol-hydrochloride\" title=\"ETHAMBUTOL HYDROCHLORIDE\">\n<title>ETHAMBUTOL HYDROCHLORIDE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1304\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/ethambutol\">Ethambutol</xref>\n</p>\n<data name=\"vtmid\">24450004</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_574205566\" title=\"Antimycobacterials\">Antimycobacterials</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP50203\" outputclass=\"indicationsAndDose\" rev=\"1.36\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>20&#8239;mg/kg once daily for 2 months (initial phase).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>15&#8239;mg/kg once daily for 2 months (initial phase).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>30&#8239;mg/kg 3 times a week for 2 months (initial phase).</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>30&#8239;mg/kg 3 times a week for 2 months (initial phase).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50270\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Optic neuritis</ph>; <ph outputclass=\"contraindication\">poor vision</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50291\" outputclass=\"cautions\" rev=\"1.15\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Elderly</ph> (in adults); <ph outputclass=\"caution\">young children</ph> (in children)</p>\n</section>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Understanding warnings</p>\n<p>Patients who cannot understand warnings about visual side-effects should, if possible, be given an alternative drug. In particular, ethambutol should be used with caution in children until they are at least 5 years old and capable of reporting symptomatic visual changes accurately.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50192\" outputclass=\"interactions\" rev=\"1.8\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (ethambutol).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50128\" outputclass=\"sideEffects\" rev=\"1.26\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Pruritus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Colour blindness</ph>; <ph outputclass=\"sideEffect\">loss of visual acuity</ph>; <ph outputclass=\"sideEffect\">optic neuritis</ph>; <ph outputclass=\"sideEffect\">peripheral neuritis</ph>; <ph outputclass=\"sideEffect\">red/green colour blindness</ph>; <ph outputclass=\"sideEffect\">restriction of visual fields</ph>; <ph outputclass=\"sideEffect\">visual disturbances</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Ocular toxicity</p>\n<p>Ocular toxicity is more common where excessive dosage is used or if the patient's renal function is impaired. Early discontinuation of the drug is almost always followed by recovery of eyesight.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50179\" outputclass=\"pregnancy\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Not known to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50303\" outputclass=\"breastFeeding\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Amount too small to be harmful.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50158\" outputclass=\"renalImpairment\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>If creatinine clearance less than 30&#8239;mL/minute, use 15&#8211;25&#8239;mg/kg (max. 2.5&#8239;g) 3 times a week.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>If creatinine clearance less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, use 15&#8211;25&#8239;mg/kg (max. 2.5&#8239;g) 3 times a week.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Risk of optic nerve damage.</p>\n<p>Should preferably be avoided in patients with renal impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>If creatinine clearance less than 30&#8239;mL/minute, monitor plasma-ethambutol concentration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50100\" outputclass=\"monitoringRequirements\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"therapeuticDrugMonitoring\">\n<sectiondiv>\n<p>&#8216;Peak&#8217; concentration (2&#8211;2.5 hours after dose) should be 2&#8211;6&#8239;mg/litre (7&#8211;22&#8239;micromol/litre); &#8216;trough&#8217; (pre-dose) concentration should be less than 1&#8239;mg/litre (4&#8239;micromol/ litre).</p>\n</sectiondiv>\n</section>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Renal function should be checked before treatment.</p>\n<p>Visual acuity should be tested by Snellen chart before treatment with ethambutol.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>In young children, routine ophthalmological monitoring recommended.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP50170\" outputclass=\"patientAndCarerAdvice\" rev=\"1.21\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Ethambutol for the treatment of tuberculosis</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/ethambutol-for-the-treatment-of-tuberculosis\">www.medicinesforchildren.org.uk/ethambutol-for-the-treatment-of-tuberculosis</xref>\n</p>\n</sectiondiv>\n</section>\r\n<section outputclass=\"generalPatientAdvice\">\r\n<sectiondiv>\r\n<p outputclass=\"title\">Ocular toxicity</p>\r\n<p>The earliest features of ocular toxicity are subjective and patients should be advised to discontinue therapy immediately if they develop deterioration in vision and promptly seek further advice.</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3604-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/ethambutol-hydrochloride\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75079\" title=\"Tablet\" namespace=\"/drugs/ethambutol-hydrochloride/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP97002\" namespace=\"/drugs/ethambutol-with-isoniazid-pyrazinamide-and-rifampicin\" title=\"ETHAMBUTOL WITH ISONIAZID, PYRAZINAMIDE AND RIFAMPICIN\" count=\"1\" rel=\"backlink\">ETHAMBUTOL WITH ISONIAZID, PYRAZINAMIDE AND RIFAMPICIN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78330\" namespace=\"/treatment-summaries/tuberculosis\" title=\"Tuberculosis\" count=\"6\" rel=\"backlink\">Tuberculosis</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1304\" namespace=\"/interactions/list-of-drug-interactions/antibacterials/ethambutol\" title=\"Ethambutol\" count=\"1\" rel=\"link\">Ethambutol</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75079\" namespace=\"/drugs/ethambutol-hydrochloride/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP3604",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/ethambutol-hydrochloride",
    "basename": "ethambutol-hydrochloride",
    "title": "ETHAMBUTOL HYDROCHLORIDE",
    "interactants": [
        {
            "id": "bnf_int_1304",
            "label": "Ethambutol"
        }
    ],
    "vtmid": "24450004",
    "drugClassification": [
        "Antimycobacterials"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)",
                        "html": "Tuberculosis, in combination with other drugs (standard unsupervised 6-month treatment)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "20 mg/kg once daily for 2 months (initial phase).",
                        "html": "<p>20&#8239;mg/kg once daily for 2 months (initial phase).</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "15 mg/kg once daily for 2 months (initial phase).",
                        "html": "<p>15&#8239;mg/kg once daily for 2 months (initial phase).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)",
                        "html": "Tuberculosis, in combination with other drugs (intermittent supervised 6-month treatment) (under expert supervision)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "30 mg/kg 3 times a week for 2 months (initial phase).",
                        "html": "<p>30&#8239;mg/kg 3 times a week for 2 months (initial phase).</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "30 mg/kg 3 times a week for 2 months (initial phase).",
                        "html": "<p>30&#8239;mg/kg 3 times a week for 2 months (initial phase).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Optic neuritis",
                "html": "Optic neuritis"
            },
            {
                "type": "contraindications",
                "textContent": "poor vision",
                "html": "poor vision"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Elderly in adults",
                "html": "Elderly in adults",
                "specificity": {
                    "patientType": "adults"
                }
            },
            {
                "type": "cautions",
                "textContent": "young children in children",
                "html": "young children in children",
                "specificity": {
                    "patientType": "children"
                }
            }
        ],
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "title": "Understanding warnings",
                "textContent": "Patients who cannot understand warnings about visual side-effects should, if possible, be given an alternative drug. In particular, ethambutol should be used with caution in children until they are at least 5 years old and capable of reporting symptomatic visual changes accurately.",
                "html": "<p>Patients who cannot understand warnings about visual side-effects should, if possible, be given an alternative drug. In particular, ethambutol should be used with caution in children until they are at least 5 years old and capable of reporting symptomatic visual changes accurately.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (ethambutol).",
                "html": "<p>Appendix 1 (ethambutol).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Pruritus",
                        "html": "Pruritus",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Colour blindness",
                        "html": "Colour blindness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "loss of visual acuity",
                        "html": "loss of visual acuity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "optic neuritis",
                        "html": "optic neuritis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuritis",
                        "html": "peripheral neuritis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "red/green colour blindness",
                        "html": "red/green colour blindness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "restriction of visual fields",
                        "html": "restriction of visual fields",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "visual disturbances",
                        "html": "visual disturbances",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Ocular toxicity",
                "textContent": "Ocular toxicity is more common where excessive dosage is used or if the patient's renal function is impaired. Early discontinuation of the drug is almost always followed by recovery of eyesight.",
                "html": "<p>Ocular toxicity is more common where excessive dosage is used or if the patient's renal function is impaired. Early discontinuation of the drug is almost always followed by recovery of eyesight.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Not known to be harmful.",
                "html": "<p>Not known to be harmful.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Amount too small to be harmful.",
                "html": "<p>Amount too small to be harmful.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "If creatinine clearance less than 30 mL/minute, use 15&#8211;25 mg/kg (max. 2.5 g) 3 times a week.",
                "html": "<p>If creatinine clearance less than 30&#8239;mL/minute, use 15&#8211;25&#8239;mg/kg (max. 2.5&#8239;g) 3 times a week.</p>"
            },
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "If creatinine clearance less than 30 mL/minute/1.73 m2, use 15&#8211;25 mg/kg (max. 2.5 g) 3 times a week.",
                "html": "<p>If creatinine clearance less than 30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>, use 15&#8211;25&#8239;mg/kg (max. 2.5&#8239;g) 3 times a week.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Risk of optic nerve damage.\n\nShould preferably be avoided in patients with renal impairment.",
                "html": "<p>Risk of optic nerve damage.</p><p>Should preferably be avoided in patients with renal impairment.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "If creatinine clearance less than 30 mL/minute, monitor plasma-ethambutol concentration.",
                "html": "<p>If creatinine clearance less than 30&#8239;mL/minute, monitor plasma-ethambutol concentration.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "therapeuticDrugMonitoring": [
            {
                "type": "therapeuticDrugMonitoring",
                "textContent": "&#8216;Peak&#8217; concentration (2&#8211;2.5 hours after dose) should be 2&#8211;6 mg/litre (7&#8211;22 micromol/litre); &#8216;trough&#8217; (pre-dose) concentration should be less than 1 mg/litre (4 micromol/ litre).",
                "html": "<p>&#8216;Peak&#8217; concentration (2&#8211;2.5 hours after dose) should be 2&#8211;6&#8239;mg/litre (7&#8211;22&#8239;micromol/litre); &#8216;trough&#8217; (pre-dose) concentration should be less than 1&#8239;mg/litre (4&#8239;micromol/ litre).</p>"
            }
        ],
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Renal function should be checked before treatment.\n\nVisual acuity should be tested by Snellen chart before treatment with ethambutol.",
                "html": "<p>Renal function should be checked before treatment.</p><p>Visual acuity should be tested by Snellen chart before treatment with ethambutol.</p>"
            },
            {
                "type": "patientParameters",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "In young children, routine ophthalmological monitoring recommended.",
                "html": "<p>In young children, routine ophthalmological monitoring recommended.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/ethambutol-for-the-treatment-of-tuberculosis",
                        "label": "www.medicinesforchildren.org.uk/ethambutol-for-the-treatment-of-tuberculosis"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Ethambutol for the treatment of tuberculosis",
                "textContent": "www.medicinesforchildren.org.uk/ethambutol-for-the-treatment-of-tuberculosis",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/ethambutol-for-the-treatment-of-tuberculosis\">www.medicinesforchildren.org.uk/ethambutol-for-the-treatment-of-tuberculosis</xref>\n</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Ocular toxicity",
                "textContent": "The earliest features of ocular toxicity are subjective and patients should be advised to discontinue therapy immediately if they develop deterioration in vision and promptly seek further advice.",
                "html": "<p>The earliest features of ocular toxicity are subjective and patients should be advised to discontinue therapy immediately if they develop deterioration in vision and promptly seek further advice.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75079",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP97002",
                "label": "ETHAMBUTOL WITH ISONIAZID, PYRAZINAMIDE AND RIFAMPICIN",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78330",
                "label": "Tuberculosis",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1304",
                "label": "Ethambutol",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75079",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}